Breaking News
March 19, 2018 - AcelRx Announces Receipt of Type A FDA Meeting Minutes and Plans to Resubmit the DSUVIA New Drug Application in Q2 2018
March 19, 2018 - Eye Docs Adopt EHRs Despite Reservations
March 19, 2018 - CRISPR enhances cancer immunotherapy
March 19, 2018 - Study finds first evidence of delayed aging among Americans
March 19, 2018 - Essential oils linked to abnormal breast development in boys
March 19, 2018 - ‘Tummy Tuck’ Relieved Postpartum Back Pain/Incontinence
March 19, 2018 - New biomarkers for neuroblastoma, a type of cancer in children
March 19, 2018 - Hookah Smoking Carries a Poisoning Risk
March 19, 2018 - Do Mood and Anxiety Affect MS Disability?
March 19, 2018 - Mean depth of ultrasonographic penetration greater in autism
March 19, 2018 - Platypus milk may help combat antibiotic resistance
March 19, 2018 - U.S. IDE study of THERMOCOOL SMARTTOUCH SF Catheter completes patient enrollment
March 18, 2018 - E-cigarette use exposes adolescents to potentially cancer-causing chemicals
March 18, 2018 - GOP Senator: Solve Opioid Crisis Through Community, Not Policy
March 18, 2018 - Why is ADHD more common in boys than girls?
March 18, 2018 - Measles alert after two passengers with the disease fly into US
March 18, 2018 - FDA looks to remove nicotine from cigarettes
March 18, 2018 - FDA moves to cut nicotine in cigarettes, helping smokers kick habit
March 18, 2018 - Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis
March 18, 2018 - Surgery Tied to Better Outcomes in Kids with T2D
March 18, 2018 - Scientists use nanotechnology to detect molecular biomarker for osteoarthritis
March 18, 2018 - Research establishes use of chimeric cells as potential therapy for Duchenne muscular dystrophy
March 18, 2018 - Researcher working to develop improved endoscopic probe for colonoscopies
March 18, 2018 - Researchers develop way to sequence entire fetal genome by modifying prenatal testing method
March 18, 2018 - FDA Approves PDUFA Fee Waiver for Gimoti New Drug Application
March 18, 2018 - P2Y12 Tx Subsidy Yields Positive Response from Docs, Patients
March 18, 2018 - Are Proteins in Formula Linked to Type 1 Diabetes?
March 18, 2018 - Exercise does not seem to increase bone marrow edema in healthy people
March 18, 2018 - Researchers delineate architecture of nuclear pore complex in yeast cells
March 18, 2018 - ‘It’s Just Ghetto-izing People’: What We Heard This Week
March 18, 2018 - Alzheimer’s disease: Neuronal loss very limited
March 18, 2018 - Study reveals impact of intense, changing work schedules experienced by medical interns
March 18, 2018 - Jobs That Keep the Mind Sharp … Even Into Retirement
March 18, 2018 - Facial Scarring Improved with Botulinum Toxin
March 18, 2018 - Data detectives shift suspicions in Alzheimer’s to inside villain
March 18, 2018 - Shorter Preventive TB Tx Effective for HIV+ Patients
March 18, 2018 - New technique for identifying alcoholism puts treatment options at patients’ and providers’ fingertips
March 18, 2018 - Researchers uncover four microRNAs as potential biomarkers for atrial fibrillation
March 18, 2018 - IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
March 18, 2018 - OncoBreak: Learning from Silence; ‘Rigged’ Drug System; NCCN Guidelines Questioned
March 18, 2018 - The coffee cannabis connection
March 18, 2018 - Novel centrifugal-flow pump for heart failure patients provides improved long-term outcomes
March 18, 2018 - U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
March 18, 2018 - Cath Lab Recap: iFR vs FFR $$; Ridaforolimus-Eluting Stent
March 18, 2018 - Tree care workers need better training to handle dangers on the job, study finds
March 18, 2018 - Dementia patients do not undergo diagnostic evaluation at onset of disease, study finds
March 18, 2018 - Transplanting enhanced interneurons restores brain rhythms in mouse model of Alzheimer’s
March 18, 2018 - Gene Therapy Flops for Critical Limb Ischemia
March 17, 2018 - Study spotlights risks in anesthesiologist handoffs
March 17, 2018 - Verb fluency test may be useful tool for differential diagnosis of cognitive failure
March 17, 2018 - Health Tip: Suggestions to Improve Your Cholesterol
March 17, 2018 - Fructans Suspect in Non-Celiac Gluten Sensitivity
March 17, 2018 - Aspirin therapy appears safe before thyroid surgery
March 17, 2018 - Minimally invasive surgical device may one day provide lasting heart repair
March 17, 2018 - UIH and RaySearch enter into new partnership
March 17, 2018 - Is BMI Too Inexact? | Medpage Today
March 17, 2018 - Sleep apnea study finds male-female differences in cerebral cortex thickness, symptoms
March 17, 2018 - Leicester research could help identify people with asthma of different severities
March 17, 2018 - Biosense Webster enrolls and treats first AF patient in clinical study of new RF balloon catheter
March 17, 2018 - Participants in rogue herpes vaccine research take legal action
March 17, 2018 - Imara Doses First Patient in Phase 2a Clinical Trial of IMR-687 for Sickle Cell Disease
March 17, 2018 - AAP: Prevent Medication Errors by Improving Processes
March 17, 2018 - Severe sleep apnea during REM sleep tied to acute CV events
March 17, 2018 - Alzheimer’s disease also affects small blood vessels
March 17, 2018 - Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
March 17, 2018 - Switching Biologics in Psoriasis Care
March 17, 2018 - Polygenic risk score may identify alzheimer’s risk in younger populations
March 17, 2018 - Genetic heart mutations account for fewer sudden and unexplained infant deaths
March 17, 2018 - Clinical trial to test efficacy of stem cell transplants in stopping ALS muscle deterioration
March 17, 2018 - Researchers team up to improve life for children with microcephaly
March 17, 2018 - Health guide for young women regarding labiaplasty
March 17, 2018 - Inhaled Nitrite Flops as HFpEF Therapy
March 17, 2018 - California mental health tax providing services to needy in L.A. County, study finds
March 17, 2018 - Cancer survivors become fatigued more quickly than their peers, study finds
March 17, 2018 - Study finds common presence of nightmares among U.S. military personnel
March 17, 2018 - Yellow fever outbreak in Brazil necessitates vaccination for travelers
March 17, 2018 - Health Tip: Waist Size May Help Predict Heart Attack
March 17, 2018 - Low-Dose Combo Pill Successfully Takes Down High BP
March 17, 2018 - Most children with sickle cell anemia not receiving key medication to stay healthy
March 17, 2018 - YCC launches new Yale Center for Immuno-Oncology
A Tribute to Dr. Ray Lipicky: The Man Who Transformed Cardiology

A Tribute to Dr. Ray Lipicky: The Man Who Transformed Cardiology

image_pdfDownload PDFimage_print

Most cardiologists assume that the way we currently think about things in cardiology has always been part of our DNA. We are strongly evidence-based, and we are skeptical of mechanisms that have no supporting data. We recognize the limitation of small trials, and we understand how missing data creates bias. We know that rigorous clinical trials are the only way to inform our use of drugs.

Has cardiology always been this way? Actually, no.

Forty years ago, thinking in cardiology was dominated by wonderful story-telling, but without much evidence. Trials were small, and many were not well designed or executed. They often focused on things that we thought were important, based on our beliefs about a disease. We knew that shortcuts commonly gave the wrong answer, but we embraced them because we did not know better.

One man made all the difference: Dr. Raymond Lipicky.

Ray led the FDA Division of Cardiac and Renal Drug Products from 1981-2002. During those 21 years, his unique intellect and way of thinking transformed the cardiovascular drug evaluation and approval process. Too slowly, his approach to cardiovascular drugs is now being adopted in other therapeutic areas.

What was special about Ray Lipicky? Each of us would probably answer that question a bit differently, as would hundreds of others whom he influenced. But in essence, it all came down to a single summary statement.

He taught us how to challenge the casual assumptions that kept getting in the way of progress.

Ray didn’t provide us with a formula as to how to think. Instead, he was exceptional at challenging our basic thought processes. If we assumed something was true, Ray wanted to know why. If we assumed that there was one way to do something, Ray might suggest three other ways.

His favorite reply: “Why do you think that?”

Many of us who were on the receiving end of that question were often stunned by it. There would be a long moment of silence, often with our jaws wide open. Ray would notice the lack of a response, and he would chuckle.

Ray had a unique chuckle. It was never condescending or judgmental; it was never intended to create discomfort. Its entire purpose was to help the listener move to a new way of thinking. The chuckle gave us permission to laugh at ourselves. When we heard the chuckle, we knew it was time to start paying attention.

Ray always asked the really tough questions. How do you know that ventricular premature beats are bad? How do you know that clots in the coronary arteries are important? How do you know that positive inotropic agents are good for the heart?

He didn’t ask these questions because he thought we would come up with answers. He asked because he wanted us to wonder whether the assumptions we had in our heads were actually true. And he pushed us to come up with a way to test our theories using logic and empirical evidence.

The four of us interacted with Ray in different ways during his tenure at FDA and beyond. Three of us were employed at FDA at various times. But Ray’s influence was felt throughout the academic cardiology community, and it was felt in every sector that was interested in cardiovascular drug development.

In the 1980s and 1990s, if you wanted to learn how to think about therapeutics, all you needed to do was to attend a public meeting of the FDA’s Cardiac and Renal Drugs Advisory Committee. In those days, the meetings discussed the pros and cons of over a dozen new chemical entities each year. At each meeting, the members of the committee typically sat along a linear table in front of an audience that was packed with hundreds of people. Ray Lipicky was at one end of the table, and Dr. Robert Temple (who had preceded Ray as Division Director) was at the other. When they had a discussion or a disagreement, you could hear some amazing intellectual discourse. For all of us, those debates opened our minds and our hearts.

Dr. Ray Lipicky passed away last week.

For everyone who works in the field of cardiology today, the loss is profound. For those of us who knew him, worked with him, learned from him, and were transformed by him, the world is suddenly left without the person who had made such a difference.

Why do we think that? Even though we can no longer hear Ray say those exact words, we will always remember them — and him.

Milton Packer

Robert M. Califf

Norman Stockbridge

Robert R. Fenichel

Packer recently consulted for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Gilead, Novo Nordisk, Relypsa, Sanofi, Takeda, and ZS Pharma. He chairs the EMPEROR Executive Committee for trials of empagliflozin for the treatment of heart failure. He was previously the co-PI of the PARADIGM-HF trial and serves on the Steering Committee of the PARAGON-HF trial, but has no financial relationship with Novartis.


last updated

Tagged with:

About author

Related Articles